Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dentsply detrey gmbh* - prilocainum hýdróklóríð; felypressinum inn - stungulyf, lausn - 30 mg+0,54 míkróg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sanofi-aventis norge as - zopiclonum inn - filmuhúðuð tafla - 7,5 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

opk biotech netherlands bv - blóðrauði glútamíð-200 (nautgripa) - blÓÐ staÐinn og gegnflÆÐi lausnir - hundar - oxyglóbín veitir stuðningi við súrefni sem stuðlar að hundum sem bæta klínísk einkenni blóðleysis í að minnsta kosti 24 klukkustundir, óháð undirliggjandi ástandi.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

provepharm sas - metýlþíóníumklóríð - methemóglóbíndreyri - Öll önnur lækningavörur - bráð einkenni meðhöndlunar á methemóglóbíndreyri í lyfjum og efnaafurðum. methylthioninium i proveblue er ætlað í fullorðnir, börn og unglingar (aldrinum 0 til 17 ára).

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

aspen pharma trading limited - lidocainum inn; prilocainum inn - lyfjaplástur - 25+25 mg/plástur

Evrópusambandið - íslenska - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - blóðrauði, ofsakláði - valdar ónæmisbælandi lyf - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - blóðrauði, ofsakláði - Ónæmisbælandi lyf - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

aspen pharma trading limited - lidocainum inn; prilocainum inn - krem - 25+25 mg/g

Evrópusambandið - íslenska - EMA (European Medicines Agency)

linde healthcare ab - nituroxíð - hypertension, pulmonary; respiratory insufficiency - Önnur öndunarfæri - Þegar, í tengslum við öndunarvél stuðning og öðrum viðeigandi virk efni, er ætlað:fyrir meðferð nýbura stærri 34 vikur meðgöngu með öndunarbilun tengslum við klínískum eða hjartaómunar vísbendingar lungum háan blóðþrýsting, til að bæta súrefni og til að draga úr þörf fyrir extracorporeal himna súrefnismettun;eins og hluti af meðferð. - og eftir aðgerð lungnaháþrýstingi í fullorðnir og nýfædd börn, börn og smábörn, börn og unglingar, aldri 0-17 ár í tengslum að hjartaaðgerð, í því skyni að vali minnka lungum slagæð þrýsting og bæta rétt op virka og súrefnismettun.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

alfasigma s.p.a. - metýlþíóníumklóríð - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.